The Evolution of Oncology Companion Diagnostics from Signal Transduction to Immuno-Oncology

详细信息    查看全文

• 作者：Nicholas C. Dracopoli¹ ; ^{ndracopo@its.jnj.com} ; Mark S. Boguski² ; ^{mark.boguski@precisionready.com}
• 关键词：immunotherapy ; precision medicine ; predictive biomarkers ; signal transduction inhibitors
• 刊名：Trends in Pharmacological Sciences
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：38
• 期：1
• 页码：41-54
• 全文大小：2513 K
• 卷排序：38

文摘

Sixteen oncology drugs have been approved with a companion diagnostic (CDx) test by the FDA. These represent only 9.6% of the 167 oncology drug approvals since 1998, the year the first CDx test for Herceptin was approved. The great majority of CDx tests are for drugs that inhibit signal transduction pathways by either inhibiting the intracellular kinase activity with a small molecule or preventing ligand-induced receptor activation with a monoclonal antibody. In most of these cases, prospective patient selection for the biomarker-positive subpopulation was initiated in or before Phase II. The development of CDx tests for emerging immunotherapies will be more complicated because they are not dependent on driver mutations in the drug target, the mechanism of action is often pleiotropic, and will require both protein and cell-based assays to evaluate the interaction of the tumor with the immune system. Consequently, we will need to develop new biomarker strategies for the development of immunotherapies and to determine whether the optimum strategy is to release a prior checkpoint blockade in patients with a suppressed immune response, or to prime a new immune response to the tumor.